J&J: positive results from post-marketing study
(CercleFinance.com) - J&J reports that Shockwave Medical, a subsidiary of Johnson & Johnson MedTech, has announced the 30-day results of a post-marketing study evaluating the safety and efficacy of the Shockwave Peripheral IVL system for treating calcified peripheral lesions below the knee, particularly in patients with critical limb ischemia (CLTI).
The favorable results, presented at the VIVA annual meeting, show that both safety and efficacy targets were met.
The study, led by healthcare experts, included 250 patients with complex characteristics, 80% of whom had CLTI and 70% of whom were diabetic.
Dr. Venita Chandra emphasized that VILI (intravascular lithotripsy) can offer a safe and effective treatment option for these challenging patients, improving their quality of life and Rutherford grading.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The favorable results, presented at the VIVA annual meeting, show that both safety and efficacy targets were met.
The study, led by healthcare experts, included 250 patients with complex characteristics, 80% of whom had CLTI and 70% of whom were diabetic.
Dr. Venita Chandra emphasized that VILI (intravascular lithotripsy) can offer a safe and effective treatment option for these challenging patients, improving their quality of life and Rutherford grading.
Copyright (c) 2024 CercleFinance.com. All rights reserved.